Artiva Biotherapeutics Inc
ARTV4.030USD
+0.160+4.13%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
98.92MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Artiva Biotherapeutics Inc Unternehmen
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Its product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient's treatment location. Its lead product candidate, AlloNK, is being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in patients with autoimmune diseases and cancers, such as systemic lupus erythematosus (SLE), lupus nephritis (LN), RA, PV, the ANCA-associated vasculitis subtypes GPA/MPA, and B-NHL. AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted mAbs in an ongoing Phase I/Ib trial in SLE with or without LN and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.
Artiva Biotherapeutics Inc Informationen
BörsenkürzelARTV
Name des UnternehmensArtiva Biotherapeutics Inc
IPO-datumJul 19, 2024
CEOAslan (Fred)
Anzahl der mitarbeiter89
WertpapierartOrdinary Share
GeschäftsjahresendeJul 19
Addresse5505 Morehouse Drive
StadtSAN DIEGO
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl92121
Telefon18582674467
Websitehttps://www.artivabio.com/
BörsenkürzelARTV
IPO-datumJul 19, 2024
CEOAslan (Fred)
Führungskräfte von Artiva Biotherapeutics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Heather Raymon, Ph.D.
Dr. Heather Raymon, Ph.D.
Senior Vice President - Research and Early Development
Senior Vice President - Research and Early Development
106.84K
+67253.00%
Ms. Neha Krishnamohan
Ms. Neha Krishnamohan
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
2.41K
-1341.00%
Dr. Brian Daniels, M.D.
Dr. Brian Daniels, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Fred Aslan, M.D.
Dr. Fred Aslan, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Christopher P. Horan
Mr. Christopher P. Horan
Chief Technical Operations Officer
Chief Technical Operations Officer
--
--
Ms. Jennifer Bush
Ms. Jennifer Bush
Chief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officer
Chief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officer
--
--
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Independent Director
Independent Director
--
--
Dr. Diego Miralles, M.D.
Dr. Diego Miralles, M.D.
Director
Director
--
--
Dr. Laura Stoppel, Ph.D.
Dr. Laura Stoppel, Ph.D.
Independent Director
Independent Director
--
--
Dr. Alison Moore, Ph.D.
Dr. Alison Moore, Ph.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Heather Raymon, Ph.D.
Dr. Heather Raymon, Ph.D.
Senior Vice President - Research and Early Development
Senior Vice President - Research and Early Development
106.84K
+67253.00%
Ms. Neha Krishnamohan
Ms. Neha Krishnamohan
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
2.41K
-1341.00%
Dr. Brian Daniels, M.D.
Dr. Brian Daniels, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Fred Aslan, M.D.
Dr. Fred Aslan, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Christopher P. Horan
Mr. Christopher P. Horan
Chief Technical Operations Officer
Chief Technical Operations Officer
--
--
Ms. Jennifer Bush
Ms. Jennifer Bush
Chief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officer
Chief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officer
--
--
Umsatzaufteilung
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q1
FY2022
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach RegionUSD
Name
Umsatz
Anteil
United States
0.00
0.00%
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Wed, Dec 17
Aktualisiert: Wed, Dec 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
RA Capital Management, LP
40.14%
GC Biopharma Corp
18.61%
5AM Ventures
9.59%
VR Adviser, LLC
6.56%
VenBio Partners LLC
4.68%
Andere
20.42%
Aktionäre
Aktionäre
Anteil
RA Capital Management, LP
40.14%
GC Biopharma Corp
18.61%
5AM Ventures
9.59%
VR Adviser, LLC
6.56%
VenBio Partners LLC
4.68%
Andere
20.42%
Aktionärstypen
Aktionäre
Anteil
Venture Capital
56.48%
Corporation
18.61%
Hedge Fund
5.50%
Individual Investor
5.43%
Private Equity
4.68%
Investment Advisor/Hedge Fund
3.61%
Investment Advisor
2.85%
Research Firm
1.28%
Andere
1.56%
Institutionelle Beteiligung
Aktualisiert: Mon, Dec 8
Aktualisiert: Mon, Dec 8
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
113
18.19M
82.07%
+1.82K
2025Q3
113
18.19M
82.47%
-356.42K
2025Q2
106
18.54M
87.44%
-2.45M
2025Q1
93
21.00M
87.08%
-218.92K
2024Q4
86
21.21M
85.45%
+459.05K
2024Q3
67
20.75M
65.99%
+4.72M
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
RA Capital Management, LP
9.85M
40.14%
--
--
Sep 30, 2025
GC Biopharma Corp
4.57M
18.61%
+4.57M
--
Jul 22, 2024
5AM Ventures
2.35M
9.59%
--
--
Sep 30, 2025
VR Adviser, LLC
1.61M
6.56%
--
--
Sep 30, 2025
VenBio Partners LLC
1.15M
4.68%
--
--
Sep 30, 2025
Aslan (Fred M.D.)
805.78K
3.28%
+797.75K
+9937.16%
Dec 15, 2025
Citadel Advisors LLC
798.40K
3.25%
+644.66K
+419.32%
Sep 30, 2025
Franklin Advisers, Inc.
520.33K
2.12%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
280.30K
1.14%
-176.75K
-38.67%
Sep 30, 2025
Millennium Management LLC
262.16K
1.07%
-64.91K
-19.85%
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
Invesco Nasdaq Biotechnology ETF
0.01%
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Biotechnology ETF
0%
ProShares Hedge Replication ETF
0%
ProShares UltraPro Russell2000
0%
iShares Russell 2000 Growth ETF
0%
iShares Micro-Cap ETF
0%
iShares Russell 2000 ETF
0%
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
Mehr Anzeigen
Invesco Nasdaq Biotechnology ETF
Anteil0.01%
ProShares Ultra Nasdaq Biotechnology
Anteil0.01%
iShares Biotechnology ETF
Anteil0%
ProShares Hedge Replication ETF
Anteil0%
ProShares UltraPro Russell2000
Anteil0%
iShares Russell 2000 Growth ETF
Anteil0%
iShares Micro-Cap ETF
Anteil0%
iShares Russell 2000 ETF
Anteil0%
Global X Russell 2000 ETF
Anteil0%
Proshares Ultra Russell 2000
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
